Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apyx Medical (APYX) EBIT Margin (2016 - 2025)

Apyx Medical's EBIT Margin history spans 15 years, with the latest figure at 0.06% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 2149.0% year-over-year to 0.06%; the TTM value through Dec 2025 reached 12.2%, up 2698.0%, while the annual FY2025 figure was 12.2%, 2698.0% up from the prior year.
  • EBIT Margin reached 0.06% in Q4 2025 per APYX's latest filing, up from 6.46% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 0.06% in Q4 2025 to a low of 64.57% in Q1 2024.
  • Average EBIT Margin over 5 years is 35.41%, with a median of 37.37% recorded in 2021.
  • Peak YoY movement for EBIT Margin: skyrocketed 10753bps in 2021, then plummeted -3699bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 10.06% in 2021, then plummeted by -368bps to 47.05% in 2022, then increased by 16bps to 39.39% in 2023, then soared by 46bps to 21.43% in 2024, then surged by 100bps to 0.06% in 2025.
  • Per Business Quant, the three most recent readings for APYX's EBIT Margin are 0.06% (Q4 2025), 6.46% (Q3 2025), and 22.63% (Q2 2025).